PPD CorEvitas Dermatology Registries
PPD™ CorEvitas™ Clinical Registries track information about the health status of patients and the care they receive, bringing together large regulatory-grade proprietary data sets to analyze patterns in treatment and outcomes, informing best practices and treatment decisions.
Granular, longitudinal outcome measures are collected during regular visits, including clinician-reported outcomes, lab measures and treatment history, as well as patient-reported outcomes (PROs) assessing symptom impact and quality of life. Drug safety data are also collected, including serious adverse events and other adverse events of special interest.
Developed and maintained under the guidance of scientific advisors who are preeminent experts in their fields, these registries feature exceptional data completeness and scientific rigor.
Now enrolling qualified sites for our dermatology registries!
CorEvitas Adolescent Alopecia Areata Registry
Established in 2025
This international registry prospectively collects detailed patient-level data on a cohort of adolescent subjects, to evaluate the long-term safety and effectiveness of routine treatments in real-world clinical care. Data collected support research on the natural history of the disease, treatment effectiveness and safety, adolescent growth and development, drug risk-benefit evaluation, and unmet need. Additionally, this registry provides real-world evidence to inform clinical decision-making for patients and providers.
Examples of the robust outcomes measures collected in the CorEvitas Adolescent Alopecia Areata Registry:
Are you interested in utilizing these data?
Clinician-Reported Outcomes
- Alopecia Areata Investigator Global Assessment Scale (AA-IGA)
- Severity of Alopecia Tool (SALT)
- ClinRO Measure for Eyebrow Hair Loss
- ClinRO Measure for Nail Appearance
- ClinRO Measure for Eyelash Hair Loss
Patient-Reported Outcomes
- Alopecia Areata Patient Priority Outcomes (AAPPO)
- Patient Scalp Hair Assessment
- PRO Measures for Eye Irritation and Nail Appearance
- Patient Health Questionnaire (PHQ-4)
- PROMIS Pediatric Stigma (8a)
- PROMIS Pediatric Sleep Disturbance (4a)
Want to join a registry to help improve patient health outcomes?
Join our Registry Investigator Network
CorEvitas Adolescent Atopic Dermatitis Registry
Established in 2024
This international registry addresses a critical unmet need for real-world evidence and adolescent-specific developmental and safety data related to novel therapies for Atopic Dermatitis (AD). Data collected enables the natural history of the disease and evaluation of the effectiveness and safety of medications used for the treatment of AD to support ongoing risk-benefit evaluation by drug manufacturers and regulators.
Examples of the robust outcomes measures collected in the CorEvitas Adolescent Atopic Dermatitis Registry
Clinician-reported outcomes
- Validated Investigator Global Assessment for Atopic Dermatitis (Viga-AD)
- Assessment of nail changes due to AD (VAS)
- Atopic dermatitis Body Surface Area (BSA)
- Eczema Area and Severity Index (EASI) (calculated)
- SCORing Atopic Dermatitis (SCORAD)
- Pubertal Progression: Tanner Staging Assessment
Patient-reported outcomes
- Atopic Dermatitis Control Tool (ADCT)
- Patient Oriented Eczema Measure (POEM)
- SCORAD Average Pruritus – 3 days (VAS)
- Children’s Dermatology Life Quality Index (CDLQI)
- Patient Health Questionnaire (PHQ-4)
Are you interested in utilizing these data?
Want to join a registry to help improve patient health outcomes?
Join our Registry Investigator Network
CorEvitas Alopecia Areata Registry
This prospective, observational cohort registry is the first of its kind in alopecia areata (AA). Using a standard protocol to collect deep regulatory-grade data in real-world care settings, including patient-reported outcomes, this registry helps advance the understanding and utilization of novel and effective therapies for individuals afflicted by this disease.
Explore data from our registry
Study visits
Patients
Dermatologists
Examples of the robust outcome measures collected in the CorEvitas Alopecia Areata Registry
Clinician-reported outcomes
- Severity of Alopecia Tool (SALT)
- Alopecia Areata-Investigator Global Assessment (AA-IGA)
- ClinRo Measures for: Eyebrow Hair Loss™, Eyelash Hair Loss™ and Nail Appearance™
- Alopecia Areata Scale (AAS)
- Clinical Features-Ophiasis and Androgenic Areata
Patient-reported outcomes
- Scalp Hair Assessment PRO™
- PRO Measures for Eyebrows™, Eyelashes™, Eye Irritations™, and Nail Appearance™
- Alopecia Areata Symptom Impact Scale (AASIS)
- Dermatology Life Quality Index (DLQI)
- Skindex-16
Active safety assessments
Active safety assessments using structured data fields are collected with supporting documents to meet regulatory requirements and post-marketing commitments.
Are you interested in utilizing these data?
Want to join a registry to help improve patient health outcomes?
Join our Registry Investigator Network
CorEvitas Atopic Dermatitis Registry
Leverage real-world data beyond clinical features, medication history and comorbidities in atopic dermatitis. Our comprehensive atopic dermatitis registry captures data across numerous clinician- and patient-reported outcomes to help uncover unmet needs, treatment effectiveness and product safety, and to help support research, decision-making and peri- and post-launch regulatory requirements.
Explore data from our registry
Study visits
Patients
Dermatologists
Examples of the robust outcome measures collected in the CorEvitas Atopic Dermatitis Registry
Clinician-reported outcomes
- Body Surface Area (BSA) Involvement
- Eczema Area and Severity Index (EASI)
- SCORing Atopic Dermatitis (SCORAD)
- Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD)
- Nail changes due to atopic dermatitis (graduated Visual Analogue Scale)
Patient-reported outcomes
- Patient global assessments of disease control and severity
- Dermatology Life Quality Index (DLQI)
- Patient-Oriented Eczema Measure (POEM)
- Atopic Dermatitis Control Tool (ADCT)
- Peak pruritus Numerical Rating Scale
- Sleeplessness and average pruritus (SCORAD)
- Skin Pain Numerical Rating Scale
- Fatigue Numerical Rating Scale
- Itch triggers (PROMIS)
- Work Productivity and Activity Impairment (WPAI)
Active safety assessments
- Active safety assessments using structured data fields are collected with supporting documents to meet regulatory requirements and post-marketing commitments.
Are you interested in utilizing these data?
Want to join a registry to help improve patient health outcomes?
Join our Registry Investigator Network
CorEvitas Generalized Pustular Psoriasis (GPP) Registry
Established in 2024
Our GPP registry addresses an unmet need for real-world evidence (RWE) related to the clinician-reported and patient-reported outcomes of patients with GPP.
This registry prospectively collects detailed patient-level real-world data, enabling assessment of the natural history of the disease and treatment patterns, along with the prevalence and incidence of comorbidities in patients with the disease.
Examples of the robust outcome measures collected in the CorEvitas GPP Registry
Clinician-reported outcomes
- Generalized Pustular Psoriasis Physician Global Assessment (GPPGA)
- Generalized Pustular Psoriasis Area Severity Index (GPPASI)
- Investigator Global Assessment (IGA)
- Disease activity/flare:
- Frequency, time to resolution, triggers, medications
- Medications (dose and frequency), symptoms, complications
Patient-reported outcomes
- Dermatology Life Quality Index (DLQI)
- Work Productivity and Activity Impairment (WPAI)
- Euro-QoL Group EQ-5D-3L
- World Health Organization Five Well-Being Index (WHO-5)
- Psoriasis Epidemiology Screening Tool (PEST)
- EQ-VAS (Health State Today)
- Numeric rating scales for:
- Generalized Pustular Psoriasis, Plaque Psoriasis, Psoriatic Arthritis
- Pain (overall), skin pain, itch, skin burning, fatigue, joint pain
Are you interested in utilizing these data?
Want to join a registry to help improve patient health outcomes?
Join our Registry Investigator Network
CorEvitas Psoriasis Registry
Launched with the support of the National Psoriasis Foundation (NPF) and developed and maintained under the guidance of scientific advisors who are preeminent experts on psoriasis, the registry collects and analyzes clinician- and patient-reported outcome measures and features exceptional data completeness and scientific rigor.
Primarily used to study the safety of FDA-approved systemic therapies, the resulting real-world data and evidence can also be utilized to answer a variety of important research questions and initiatives.
Explore data from our registry
Study visits
Patients
Dermatologists
Examples of the robust outcome measures collected in the CorEvitas Psoriasis Registry
Clinician-reported outcomes
- Psoriasis Area and Severity Index (PASI)
- Body Surface Area (BSA) Involvement
- Investigator Global Assessment (IGA)
Patient-reported outcomes
- Dermatology Life Quality Index (DLQI)
- Work Productivity and Activity Impairment (WPAI)
- Euro-QoL Group EQ-5D-3L
- World Health Organization Five Well-Being Index (WHO-5)
- Patient Global Assessment
- Psoriasis Epidemiology Screening Tool (PEST)
- Pain Visual Analogue Scale
- Itch Visual Analogue Scale
- Fatigue Visual Analogue Scale
Are you interested in utilizing these data?
Want to join a registry to help improve patient health outcomes?
Join our Registry Investigator Network